Get started
Author

Izumi Hamada

Observed names: Hamada, Izumi, I. Hamada
OpenAlex ID: A5083373629
Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial
2018 · Mari Wataya-Kaneda, Yuuki Ohno, et al. · JAMA Dermatology · 68
PDF
Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders
2020 · Kotaro Yuge, Shinichiro Nagamitsu, et al. · BMC Psychiatry · 63
PDF
Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial
2021 · Masaharu Hayashi, Kazuo Mishima, et al. · Journal of Autism and Developmental Disorders · 51
Demographic and clinical characteristics of patients with zinc deficiency: analysis of a nationwide Japanese medical claims database
2024 · Hirohide Yokokawa, Yusuke Morita, et al. · Scientific Reports · 40
PDF
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
2014 · Masato Odawara, Izumi Hamada, et al. · Diabetes Therapy · 31
PDF
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial
2020 · Mari Wataya-Kaneda, Hiroshi Nagai, et al. · Dermatology and Therapy · 28
PDF
Effects of Zinc Acetate on Serum Zinc Concentrations in Chronic Liver Diseases: a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial and a Dose Adjustment Trial
2019 · Kazuhiro Katayama, Atsushi Hosui, et al. · Biological Trace Element Research · 24
PDF
Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
2015 · Masato Odawara, Mika Yoshiki, et al. · Diabetes Therapy · 8
PDF
Pharmacokinetics, Safety, and Tolerability of NPC‐21, an Anti‐Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo‐Controlled, First‐in‐Human Phase 1 Study
2022 · Kenichi Furihata, Izumi Hamada, et al. · Clinical Pharmacology in Drug Development · 6
PDF
Randomized, multicenter, active-controlled open-label study of NPC-25, zinc histidine hydrate, (non-inferiority to NOBELZIN™, zinc acetate dihydrate) for patients with hypozincemia
2024 · Daisuke Asaoka, Tomomi Ishihara, et al. · Journal of Trace Elements in Medicine and Biology · 4
Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations
2024 · Taichi Miyazaki, Daichi Hayashi, et al. · Drug Metabolism and Pharmacokinetics · 4
PDF
Efficacy and safety of intravenous fosphenytoin for patients with acute herpes zoster‐associated pain: A placebo‐controlled randomized trial
2023 · Masako Iseki, Takenobu Yamamoto, et al. · The Journal of Dermatology · 4
PDF
P-320 Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
2023 · Niels van de Donk, Darrell White, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development
2024 · Shubhadeep Chakraborty, Kshitij Aggarwal, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2
Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex
2024 · Izumi Hamada, Yoshinori Yukutake, et al. · The Journal of Dermatology · 1
PDF
1054 Sirolimus gel treatment for tuberous sclerosis complex involving facial angiofibromas and cephalic plaques: A multicenter randomized controlled trial
2018 · M. Wataya-Kaneda, Y. Ohno, et al. · Journal of Investigative Dermatology · 1
Model Platform to Predict Overall Survival for Patients with Relapsed and Refractory Multiple Myeloma
2026 · Mayu Osawa, Yiming Cheng, et al.
PDF
Right-Sizing Models: A Model Reduction Approach Applied to Models of the Treatment of Solid Tumors by Protein Degraders
2026 · Karyn Sutton, Yue Zhao, et al.
Machine Learning Augmented Tumor Growth and Survival Models: Insights from Hepatocellular Carcinoma Data
2026 · Ahmed Elmokadem, Izumi Hamada, et al.
Population Pharmacokinetics and Exposure-Response Analysis of Nivolumab in Combination with Ipilimumab in Participants with First-Line Unresectable or Advanced Hepatocellular Carcinoma to Support Benefit-Risk Assessment
2026 · Izumi Hamada, Jian Shi, et al.
Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation
2024 · Izumi Hamada, Kshitij Aggarwal, et al.
PDF
Works count: 22
Citation count: 336
H-index: 8
I10-index: 7
Year
Topic
Type